| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -6,503,698 | -4,216,707 |
| Accretion of deferred grant reimbursement | -40,213 | -27,158 |
| Depreciation of property and equipment | 214,362 | 142,759 |
| Non-cash lease expense | 37,864 | 14,629 |
| Tax payable | - | 0 |
| Stock-based compensation | 1,310,239 | 884,531 |
| Grants receivable | -434,639 | -479,875 |
| Prepaid expenses and other current assets | -165,070 | -76,371 |
| Accounts payable and accrued expenses | -19,899 | 6,377 |
| Due to related party | -20,778 | -32,209 |
| Tax receivable | 105,826 | - |
| Net cash provided by (used in) operating activities | -4,528,240 | -2,671,532 |
| Deferred grant reimbursement | 19,701 | 19,699 |
| Purchases of property and equipment | 94,929 | 81,619 |
| Net cash (used in) investing activities | -75,228 | -61,920 |
| Related party note | - | 0 |
| Deferred ipo cost | - | 0 |
| Payments on finance lease obligations | 17,155 | - |
| Net cash (used in) financing activities | -17,155 | 0 |
| Net increase (decrease) in cash, cash equivalents | -4,620,623 | -2,733,452 |
| Cash and cash equivalents at beginning of period | 9,719,310 | - |
| Cash and cash equivalents at end of period | 5,098,687 | - |
EXOZYMES INC. (EXOZ)
EXOZYMES INC. (EXOZ)